Please assess the completion status of the following clinical trial:

Trial Title: Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to give informed consent - Aged 18 years or over~* Participants with relapsed myeloma who have received 1-3 prior lines of treatment and now require further treatment~* ECOG Performance Status ≤ 2~* Required laboratory values within 14 days of registration:~  * Absolute neutrophil count ≥1.0 x 10\^9/L.~ * Platelet count ≥75x10\^9/L.~ * Haemoglobin \> 9 g/dL.~ * Bilirubin ≤1.5 x upper limit of normal~ * ALT and / or AST ≤2.5 x upper limit of normal~ * Serum creatinine ≤ 2.0 x upper limit of normal~ * Corrected calcium ≤ 2.8 mmol/L~* Life expectancy of at least 3 months~* Female participants of child-bearing potential must have a negative pregnancy test at baseline and agree to use dual methods of contraception for the duration of the study and must continue to do so for 3 months after the end of treatment. Male participants must agree to use a barrier method of contraception for the duration of the study if sexually active with a female of child-bearing potential and must continue to do so for 3 months after the end of treatment~* Participant is able to swallow capsules and is able to take or tolerate oral medications on a continuous basis.~Exclusion Criteria:~* Previous anti-tumour therapies, including prior experimental agents or approved anti-tumour small molecules and biologics, within 28 days before the start of protocol treatment. Steroid therapy to stop rapid relapse during this period is permitted, but must be stopped 7 days prior to study drug administration.~* Prior HDAC inhibitor treatment.~* Previous or concurrent active malignancies (\<12 months post end of treatment) at other sites with the exception of appropriately treated localised epithelial skin or cervical cancer.~* Participants considered to be refractory to prior bortezomib treatment or unable to tolerate treatment with bortezomib.~* Peripheral neuropathy of ≥ grade 2 severity~* Participants who have received growth factor support or platelet support within 14 days prior to registration~* Participants with uncontrolled concurrent illness or circumstances that could limit compliance with the study.~* Patients with significant cardiovascular or pulmonary disease~* Active symptomatic fungal, bacterial, and/or viral infection including known active HIV or known viral (A, B, or C) hepatitis.~* Pregnant or breast feeding females~* Unable to take corticosteroid therapy at study entry~* Participants with known hypersensitivity to any components of bortezomib, (such as boron, mannitol), vorinostat or dexamethasone.~* Participant has known CNS metastases and/or carcinomatous meningitis.~* Participants with a history of a gastrointestinal surgery or other procedures that might, in the opinion of the Investigator, interfere with the absorption or swallowing of the study drug(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat Velcade Dexamethasone (VVD) (Type: EXPERIMENTAL): Up to 8 cycles of VVD followed by vorinostat maintenance until disease progression.~Cycles 1-8 (21-day cycle)~* Velcade: 1.3mg/m2 (subcutaneous) on days 1, 4, 8 and 11~* Dexamethasone: 20 mg (PO) on days 1, 2, 4, 5, 8, 9, 11 and 12~* Vorinostat: 400mg (PO) on days 1-4, 8-11, 15-18 Maintenance (28-day cycle)~* Vorinostat: 400mg PO on 1-4 and 15-18

Based on this trial design, predict the completion outcome and termination type (if applicable).